Spurrier B, Sampson J, Gorny M, Zolla-Pazner S, Kong X
J Virol. 2014; 88(8):4100-12.
PMID: 24478429
PMC: 3993739.
DOI: 10.1128/JVI.03153-13.
ORourke S, Schweighardt B, Phung P, Mesa K, Vollrath A, Tatsuno G
J Virol. 2012; 86(22):12105-14.
PMID: 22933284
PMC: 3486483.
DOI: 10.1128/JVI.01352-12.
Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker J
J Virol. 2012; 86(22):12115-28.
PMID: 22933274
PMC: 3486499.
DOI: 10.1128/JVI.01632-12.
Bar K, Tsao C, Iyer S, Decker J, Yang Y, Bonsignori M
PLoS Pathog. 2012; 8(5):e1002721.
PMID: 22693447
PMC: 3364956.
DOI: 10.1371/journal.ppat.1002721.
Schader S, Colby-Germinario S, Quashie P, Oliveira M, Ibanescu R, Moisi D
Antimicrob Agents Chemother. 2012; 56(8):4257-67.
PMID: 22615295
PMC: 3421599.
DOI: 10.1128/AAC.00639-12.
Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.
Dey A, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K
PLoS One. 2012; 7(1):e30233.
PMID: 22291921
PMC: 3265465.
DOI: 10.1371/journal.pone.0030233.
Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer.
Liu L, Cimbro R, Lusso P, Berger E
Proc Natl Acad Sci U S A. 2011; 108(50):20148-53.
PMID: 22128330
PMC: 3250183.
DOI: 10.1073/pnas.1104840108.
Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.
Krachmarov C, Lai Z, Honnen W, Salomon A, Gorny M, Zolla-Pazner S
J Virol. 2011; 85(20):10730-40.
PMID: 21835798
PMC: 3187505.
DOI: 10.1128/JVI.00365-11.
Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.
van Gils M, Edo-Matas D, Bowles E, Burger J, Stewart-Jones G, Schuitemaker H
J Virol. 2011; 85(16):8443-8.
PMID: 21653664
PMC: 3147988.
DOI: 10.1128/JVI.05214-11.
Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.
van Gils M, Bunnik E, Boeser-Nunnink B, Burger J, Terlouw-Klein M, Verwer N
J Virol. 2011; 85(14):6986-95.
PMID: 21593147
PMC: 3126602.
DOI: 10.1128/JVI.00268-11.
Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, Aldunate M
Antiviral Res. 2011; 90(3):195-9.
PMID: 21459115
PMC: 3115201.
DOI: 10.1016/j.antiviral.2011.03.186.
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.
Nawaz F, Cicala C, Ryk D, Block K, Jelicic K, McNally J
PLoS Pathog. 2011; 7(2):e1001301.
PMID: 21383973
PMC: 3044691.
DOI: 10.1371/journal.ppat.1001301.
HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV.
Cicala C, Arthos J, Fauci A
J Transl Med. 2011; 9 Suppl 1:S2.
PMID: 21284901
PMC: 3105502.
DOI: 10.1186/1479-5876-9-S1-S2.
Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.
Barroso H, Borrego P, Bartolo I, Maria Marcelino J, Familia C, Quintas A
PLoS One. 2011; 6(1):e14548.
PMID: 21283793
PMC: 3024314.
DOI: 10.1371/journal.pone.0014548.
Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.
ORourke S, Schweighardt B, Phung P, Fonseca D, Terry K, Wrin T
J Virol. 2010; 84(21):11200-9.
PMID: 20702624
PMC: 2953176.
DOI: 10.1128/JVI.00790-10.
Conserved structural elements in the V3 crown of HIV-1 gp120.
Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny M
Nat Struct Mol Biol. 2010; 17(8):955-61.
PMID: 20622876
DOI: 10.1038/nsmb.1861.
Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.
Bellows M, Floudas C
Curr Drug Targets. 2010; 11(3):264-78.
PMID: 20210752
PMC: 2894634.
DOI: 10.2174/138945010790711914.
Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.
van Gils M, Bunnik E, Burger J, Jacob Y, Schweighardt B, Wrin T
J Virol. 2010; 84(7):3576-85.
PMID: 20071586
PMC: 2838121.
DOI: 10.1128/JVI.02622-09.
HIV-1-specific antibody responses during acute and chronic HIV-1 infection.
Tomaras G, Haynes B
Curr Opin HIV AIDS. 2010; 4(5):373-9.
PMID: 20048700
PMC: 3133462.
DOI: 10.1097/COH.0b013e32832f00c0.
Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
Haut L, Ertl H
J Leukoc Biol. 2009; 86(4):779-93.
PMID: 19597003
PMC: 6608038.
DOI: 10.1189/jlb.0209094.